{"id":391730,"date":"2014-02-03T00:00:00","date_gmt":"2014-02-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/latron0614-biopharma-prostate-cancer-radium-223-chloride-xofigo-wave-2-launchtrends-us-2014\/"},"modified":"2026-03-31T09:05:46","modified_gmt":"2026-03-31T09:05:46","slug":"latron0614-biopharma-prostate-cancer-radium-223-chloride-xofigo-wave-2-launchtrends-us-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/latron0614-biopharma-prostate-cancer-radium-223-chloride-xofigo-wave-2-launchtrends-us-2014\/","title":{"rendered":"Prostate Cancer [Radium-223 chloride (Xofigo) (Wave 2)] | LaunchTrends | US | 2014"},"content":{"rendered":"<p>LaunchTrends\u00ae: Xofigo is a series of three post-launch syndicated reports designed to track physician perception, uptake, and the competitive environment of newly launched Xofigo (Algeta\/Bayer HealthCare\u2019s radium-223).<br \/>\nLaunchTrends\u00ae: Xofigo measures the impact of this new agent on the metastatic castrate-resistant prostate cancer (mCRPC) market following launch, based on a blend of quantitative and qualitative primary research with U.S. medical oncologists. These reports evaluate physicians\u2019 current awareness and perception of Xofigo relative to other currently available therapies for mCRPC, current and anticipated use of Xofigo, and promotional activity of Xofigo.<\/p>\n","protected":false},"template":"","class_list":["post-391730","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-prostate-cancer","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391730\/revisions"}],"predecessor-version":[{"id":394853,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391730\/revisions\/394853"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}